Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for NDA 202343

Expand all

JUVISYNC (SIMVASTATIN; SITAGLIPTIN PHOSPHATE)
10MG;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** Marketing Status: Discontinued

Active Ingredient: SIMVASTATIN; SITAGLIPTIN PHOSPHATE
Proprietary Name: JUVISYNC
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 10MG;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Reference Listed Drug: Yes
Reference Standard: No
TE Code: 
Application Number: N202343
Product Number: 004
Approval Date: Sep 18, 2012
Applicant Holder Full Name: MERCK SHARP AND DOHME CORP
Marketing Status:  Discontinued
Patent and Exclusivity Information

JUVISYNC (SIMVASTATIN; SITAGLIPTIN PHOSPHATE)
10MG;EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** Marketing Status: Discontinued

Active Ingredient: SIMVASTATIN; SITAGLIPTIN PHOSPHATE
Proprietary Name: JUVISYNC
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 10MG;EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Reference Listed Drug: Yes
Reference Standard: No
TE Code: 
Application Number: N202343
Product Number: 001
Approval Date: Oct 7, 2011
Applicant Holder Full Name: MERCK SHARP AND DOHME CORP
Marketing Status:  Discontinued
Patent and Exclusivity Information

JUVISYNC (SIMVASTATIN; SITAGLIPTIN PHOSPHATE)
20MG;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** Marketing Status: Discontinued

Active Ingredient: SIMVASTATIN; SITAGLIPTIN PHOSPHATE
Proprietary Name: JUVISYNC
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 20MG;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Reference Listed Drug: Yes
Reference Standard: No
TE Code: 
Application Number: N202343
Product Number: 005
Approval Date: Sep 18, 2012
Applicant Holder Full Name: MERCK SHARP AND DOHME CORP
Marketing Status:  Discontinued
Patent and Exclusivity Information

JUVISYNC (SIMVASTATIN; SITAGLIPTIN PHOSPHATE)
20MG;EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** Marketing Status: Discontinued

Active Ingredient: SIMVASTATIN; SITAGLIPTIN PHOSPHATE
Proprietary Name: JUVISYNC
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 20MG;EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Reference Listed Drug: Yes
Reference Standard: No
TE Code: 
Application Number: N202343
Product Number: 002
Approval Date: Oct 7, 2011
Applicant Holder Full Name: MERCK SHARP AND DOHME CORP
Marketing Status:  Discontinued
Patent and Exclusivity Information

JUVISYNC (SIMVASTATIN; SITAGLIPTIN PHOSPHATE)
40MG;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** Marketing Status: Discontinued

Active Ingredient: SIMVASTATIN; SITAGLIPTIN PHOSPHATE
Proprietary Name: JUVISYNC
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 40MG;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Reference Listed Drug: Yes
Reference Standard: No
TE Code: 
Application Number: N202343
Product Number: 006
Approval Date: Sep 18, 2012
Applicant Holder Full Name: MERCK SHARP AND DOHME CORP
Marketing Status:  Discontinued
Patent and Exclusivity Information

JUVISYNC (SIMVASTATIN; SITAGLIPTIN PHOSPHATE)
40MG;EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** Marketing Status: Discontinued

Active Ingredient: SIMVASTATIN; SITAGLIPTIN PHOSPHATE
Proprietary Name: JUVISYNC
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 40MG;EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Reference Listed Drug: Yes
Reference Standard: No
TE Code: 
Application Number: N202343
Product Number: 003
Approval Date: Oct 7, 2011
Applicant Holder Full Name: MERCK SHARP AND DOHME CORP
Marketing Status:  Discontinued
Patent and Exclusivity Information

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English